אייברנס טבליות 125 מג

Maa: Israel

Kieli: heprea

Lähde: Ministry of Health

Aktiivinen ainesosa:

PALBOCICLIB

Saatavilla:

PFIZER PHARMACEUTICALS ISRAEL LTD

ATC-koodi:

L01XE33

Lääkemuoto:

טבליות מצופות פילם

Koostumus:

PALBOCICLIB 125 MG

Antoreitti:

פומי

Prescription tyyppi:

מרשם נדרש

Valmistaja:

PFIZER INC, USA

Terapeuttinen alue:

PALBOCICLIB

Valtuutus päivämäärä:

2023-06-22

Pakkausseloste

Ibrance tablets, PIL, Israel, CC TC 021123
2023-0088988
1
" )
(
-
1986
™
75 "
™
100 "
™
125 "
:
75
,"
100
"
125
"
palbociclib 75 mg, 100 mg or 125 mg
:
6
"
"
.
.
.
,
.
.
.
.
18
.
1 .
?
,
-
HER2
,
:
•
)
(
.
•
(
fulvestrant
)
.
:
,
.
2 .
:
•
)
(
(
6
)
.
: ,
:
•
.
,
•
.
•
.
2
"
,
"
.
•
.
2
."
,
"
.
2
,
"
."
18
.
18
.
. , , ,
.
:
•
:
,
)
(
;
,
,
,
(
)
;
/
,
,
,
(
)
;
(
)
;
(
)
.
.
Ibrance tablets, PIL, Israel, CC TC 021123
2023-0088988
2
•
:
)
(
;
,
(
)
,
St. John's Wort
(
)
,
,)
(
(
)
;
.
•
,
.
.
•
:
(
,)
,
,
(
)
,
(
,
,)
,)
(
,
(
/
,)
(
,)
(
)
.
.
.
,
•
.
.
-
.
.
-
.
-
.
-
,
.
•
.
.
.
.
3
.
.
.
.
.
,
.
3 .
?
.
.
.
:
•
125
"
21
7
,
28
.
•
,
.
.
•
,
500
"
1
,
15
-
29
.
.
• .
•
.
•
:
.
,
/
.
•
.
,
.
,
,
.
.
.
,
.
Ibrance tablets, PIL, Israel, CC TC 021123
2023-0088988
3 ! . . , .
4 .
,
.
.
.
:
•
( :)
.
,
.
.
,
,
.
.
•
:
.
:
,
,
,
,
.
•
(
)
:
.
.
,
,
.
(≥ 10%) :
,
(
)
,
,
,
,
,
,
,
,
,
,
,
/
,
,
,
(
)
,
.
:
,
,
,
,
,
. , , , .
"
"
(
www.health.gov.il
)
,
"
:
https://sideeffects.health.gov.il
5 .
?
•
!
/
.
.
•
(
exp. date
)
.
.
•
-
30°C
.
.
•
/
/
.
6 .
:
Microcrystalline cellulose, succinic acid, crospovidone, magnesium
stearate, colloidal silicon dioxide,
hypromellose (E464), titanium dioxide (E171), triacetin, indigo
carmine aluminum lake (E132), iron oxide
red (E172) (75 mg and 125 mg tablets only), iron oxide yellow (E172)
(100 mg tablets only).
:
75
:"
,
,
“Pfizer”
,
-
“PBC 75”
.
100
:"
,
,
“
Pfizer
”
,
-
“
PBC 100
”
.
Ibrance tablets, PIL, Israel, CC TC 021123
2023-0088988
4
125
:"
,
,
“Pfizer”
,
-
“PBC 125”
.
21
63
.
.
:
,"
'
9
,
46725
. :
75
:"
173-61-36955-99
100
:"
173-62-36956-99
125
:"
173-63-36957-99
,
.
,
.
-
09/2023
.